is a positive inotropic and vasodilating agent that increases intracellular cyclic AMP and stimulates Ca currents. We examined its direct electrophysiological effects in isolated blood-per fused canine cardiac preparations. OPC-18790 caused an acceleration of the intraventricular conduction in association with an increase of the contractile force and the coronary blood flow. We also examined the effects of OPC-18790 on ventricular arrhythmias in canine ventricular tachycardia (VT) models. OPC-18790 in doses producing submaximal inotropic effects, 3 mg/kg, i.v., increased the total heart rate, atrial rate and decreased the blood pressure, but did not suppress or aggravate 24 and 48-hr coronary ligation VTs. OPC 18790 up to 3 mg/kg, i.v. also did not suppress or aggravate digitalis-induced VTs. However, this dose of OPC-18790 aggravated halothane-adrenaline induced VT into ventricular fibrillation and eventually death, but a lower dose of 0.3 mg/kg did not aggravate this VT. These results in canine VTs indicate that OPC 18790 is similar to other positive inotropic agents, vesnarinone, amrinone, milrinone and sulmazole. The absence of an aggravating effect of this new positive inotropic agent on digitalis and coronary ligation VTs may be advantageous in a clinical setting of combined therapy with digitalis for myocardial ischemia.
OPC-18790 is a newly synthesized positive inotropic agent with vasodilator activity and reported to be devoid of digitalis-like and catecholamine-like actions (1, 2) . Its chemical structure, (±)-6-[3-(3,4-dimethoxybenzyl amino)-2-hydroxypropoxy]-2(1H)-quinolinone, is similar to that of vesnarinone (OPC-8212), a positive inotropic drug without vasodilating action, and phosphodiesterase (PDE) inhibiting action is one of the common positive inotropic mechanisms between the two drugs (3 5) . Since the Ca channel opening effect is expected to occur from the PDE inhibiting actions of OPC-18790, alterations in the cardiac electrophysiological properties such as increas ing latent pacemaker activities or aggravation of delayed afterdepolarizations may occur and initiate or aggravate arrhythmias. On the other hand, OPC-18790 has been reported to prolong the action potential duration (1) , which may cause an antiarrhythmic action. Since the oc currence of arrhythmias is deleterious in the treatment of cardiac failure, the present experiment was designed to ex amine the effects of OPC-18790 on blood-perfused isolat ed canine sinoatrial (SA) node and papillary muscle (PM) preparations and on various types of canine ventricular arrhythmias. The ventricular tachycardia (VT) models chosen for the present study were produced by two-stage coronary ligation, digitalis intoxication and adrenaline infusion. The effects of OPC-18790 were compared with those of vesnarinone, amrinone, milrinone and sulmazole (AR-R 115) previously reported by us (6, 7).
MATERIALS AND METHODS
Cross circulated blood perfused cardiac preparations As reported earlier (8, 9), 2 mongrel dogs of either sex were used for one experiment. One dog, weighing 10-15 kg, was used as a blood donor; and from the other dog, weighing approximately 10 kg, isolated preparations were obtained. The SA node preparation consisted of the en tire right atrium, and the sinus node artery was cannulat ed via the right coronary artery. The sinoatrial rate (SAR) was measured.
The PM preparation consisted of an anterior papillary muscle attached to the interventricular septum, and the anterior septal artery (ASA) was directly cannulated (9) . This preparation was driven electrically at a fixed rate of 2 Hz. Developed tension (DT) of the PM was measured isometrically under a resting tension of 2 g. Intraventricu lar conduction time (IVCT) was also measured as the time between the stimulating artifact to the electrogram record ed at the tip of the PM by using bipolar wire electrodes. The rate of blood flow via the ASA was also measured.
Production of two-stage coronary ligation-induced VT As reported earlier (10), 6 female beagle dogs, weighing 10-12 kg, were anesthetized initially with thiopental sodium (30 mg/kg, i.v.) and then with 1.0% halothane vaporized with 100% oxygen. A left thoracotomy was per formed, and the left anterior descending coronary artery (LAD) was ligated by a two-stage ligation technique. One catheter in the left carotid artery and the other in the su perior vena cava via the left jugular vein were exterior ized at the nape of the neck and used for recording the blood pressure and intravenous injection of OPC-18790, respectively. Bipolar electrodes were sutured on the left atrium for recording the atrial electrogram.
Experiments were done about 24 and 48-hr after coro nary ligation under a conscious state. The lead II elec trocardiogram (ECG), atrial electrogram and blood pres sure were recorded continuously for 60 min by telemetry systems (Nihon Kohden, Tokyo). OPC-18790 was ad ministered into the right jugular vein as a bolus injection through the cannula inserted into the vein.
Production of digitalis-induced VT As reported earlier (11), 6 mongrel dogs of either sex, weighing 9-13 kg, were anesthetized with pentobarbital sodium (30 mg/kg, i.v.) and bilaterally vagotomized at the midcervical level. The right femoral artery and vein were cannulated for recording the blood pressure and for drug administration, respectively. The standard lead II ECG and atrial electrogram (from catheter tip electrodes placed in the right atrium via the external jugular vein) were recorded continuously. Ouabain (40 ug/kg) was ini tially administered intravenously and then followed by an additional 10 ug/kg every 20 min until stable VT was produced. OPC-18790 was administered into the right femoral vein as a bolus injection through the cannula in serted into the vein.
The standard lead II ECG, atrial electrogram from catheter tip electrodes placed in the right atrium via the right jugular vein, and the blood pressure were recorded continuously.
Production of adrenaline-induced VT
As reported earlier (12), 6 mongrel dogs of either sex, weighing 8-13 kg, were anesthetized initially with thio pental sodium (30 mg/kg, i.v.) and bilaterally vagotom ized at the midcervical level. After intubation, 1.0% halo thane vaporized with 100% oxygen was inhaled with a volume-limited ventilator. Adrenaline was infused through the left femoral vein at a rate of 2.5 3 ug/kg/min for 18 min. When stable multifocal VT was induced 3 min after adrenaline infusion, OPC-18790 was administered intravenously into the right femoral vein as a bolus in jection through the cannula inserted into the vein.
Evaluation of antiarrhythmic effects on VTs
The severity of VT was expressed by the arrhythmic ra tio: the number of ventricular ectopic beats divided by the total heart beats in a 5-sec strip of ECG (i.e., the number of ventricular ectopic beats and conducted beats). The ventricular beats were judged by the difference in the shape of the ventricular complex from the normal QRS complex. For the three VTs, the arrhythmic ratios before drug injection were about 0.8 1, and there were no spon taneous improvements in these ratios. If the arrhythmic ratio after drug administration decreased or increased sig nificantly from the 0 time value, the drug was considered to have an antiarrhythmic or proarrhythmic effect, respec tively.
Statistics
In cross-circulated, blood-perfused experiments, data are expressed as the mean±S.E. The doses of OPC-18790 that produced a 15010 or 50% change in the parameters of the cross circulated blood-perfused cardiac prepara tions were determined from the dose-response curves. The doses that produced a 15010 or 50010 decrease were determined from dose-response curves fitted by the least squares method.
Data are expressed as the mean±S.D. in the experi ments for two-stage coronary ligation-, digitalis and adrenaline-induced VTs. Analysis of variance (ANOVA) and the Dunnett's test for paired data were used for the determination of statistically significant differences be tween the mean values obtained at various times after treatment and the pretreatment, 0 time, values. A P value of 0.05 or less was considered statistically significant. All statistical calculations were done with a Macintosh IICX computer with Statview 512+ (Abacus Concepts, Inc., Berkeley, CA, USA) and Excel (Microsoft Corporation, USA) software.
All experiments were performed in accordance with the Guidelines for Animal Experiments, Yamanashi Medical University.
RESULTS
Direct cardiac effects of OPC-18790 on blood perfused isolated canine cardiac preparations OPC-18790 given intraarterially through the rubber tube connected to the coronary artery cannula increased the DT (control value: 4.0-±:0.9g, n=5) dose-depend ently (1-300 pg) . The effective positive inotropic dose producing a 50% increase was calculated to be 160 pg (Fig. 1) . OPC-18790 also increased the flow rate of the ASA (control value: 8 _±:3 ml/min, n = 5), and the effec tive dose producing a 50% increase in the coronary blood flow was 150 pg. IVCT (control value: 70±5 msec, n=6) was decreased by OPC-18790, and the effective dose producing a 15% decrease was calculated to be 320 pg. In the SA node preparation, OPC-18790 in lower doses in creased initially and then decreased the SA rate (control value: 76±9 beats/min, n=6). Higher doses had negative chronotropic effects, and only the steady state negative chronotropic effects are plotted in Fig. 1 . These effects ex cept for those on the IVCT were almost the same as those reported previously (1). 
Effects of OPC-18790 on two-stage coronary ligation-in duced VT
Conscious beagles 24 hr after coronary ligation showed sustained VT. Application of OPC-18790 at a dose of 3 mg/kg to such dogs caused a significant increase in the total heart rate and a significant decrease in the blood pres sure. However, the treatment produced no significant changes in the arrhythmic ratio (Fig. 2) . The dogs did not show any appreciable side effects in their central nervous systems.
The same dogs were used the next day for the study of OPC-18790 effects on the 48-hr VT. The arrhythmic ratio became lower, about 0.8 at 5 and 0 min, indicating that the 48-hr VT was less severe. At the same dose (3 mg/kg), OPC-18790 tended to increase the arrhythmic ratio and decreased the conducted beats soon after injection. The total heart rate also increased, but there were no decreases in the blood pressure, and there was no appearance of more severe ventricular fibrillation (VF).
Effects of OPC-18790 on digitalis-induced VT
After injection of a total dose of 70-90 pg/kg oua bain, almost all the beats were of ventricular origin (Fig.  3) . This VT continued for at least 1 hr. The maximum dose of OPC-18790 (3 mg/kg) did not aggravate this VT, but instead showed a tendency to suppress this VT, name ly increasing the number of conducted beats and decreas ing the arrhythmic ratio, although this was not statistical ly significant. This dose of OPC-18790 barely altered the other parameters, except for a late decrease in the blood pressure. Such blood pressure decreases might have been produced by the discontinuation of ouabain after OPC 18790 injection, because a similar late decrease of the blood pressure was observed in dogs treated with many other drugs (11) .
Effects of OPC-18790 on adrenaline-induced VT
Adrenaline infusion at a rate of 2.5 to 3 pg/kg/min in duced VT as shown by the sudden increase in the number of ventricular ectopic beats (Fig. 4) . Because OPC-17890 at 1 and 3 mg/kg aggravated this adrenaline VT and induced VF, a lower dose, 0.3 mg/kg, was examined. Though 2 out of 8 dogs fibrillated after OPC-18790 at this dose, 6 dogs did not show VF; Figure 4 summarizes the results from these 6 dogs, showing the effect of 0.3 mg/kg OPC-18790 on adrenaline VT. This low dose of OPC 18790 had a minimal effect on the total heart rate, atrial rate and blood pressure and did not aggravate adrenaline VT. 
DISCUSSION
The present experiments have shown that the positive inotropic agent OPC-18790 aggravates adrenaline VTs, but not digitalis and two-stage coronary ligation VTs. Our previous experiments using three VT models showed that coronary ligation-induced and digitalis-induced VTs are Na channel-dependent, because they are suppressed by class I antiarrhythmic drugs, while adrenaline VT is Ca channel-dependent, because it is suppressed by class II 8-blockers and class IV Ca channel blockers (13) . Like other new positive inotropic agents (6, 7), which are phos phodiesterase inhibitors and increase cardiac Ca current, OPC-18790 was shown to aggravate adrenaline VTs. The 1-3 mg/kg OPC-18790 did not aggravate digitalis and two-stage coronary ligation VTs; the maximum tolerable dose for adrenaline VT was 0.3 mg/kg. In our previous study (6) , vesnarinone up to 3 mg/kg did not aggravate digitalis VT, but aggravated adrenaline VT, and the maxi mum tolerable dose for adrenaline VT was 0.5 mg/kg. Also 3 mg/kg amrinone and sulmazole did not aggravate digitalis VT, but the maximum tolerable dose for adrena line VT was 1 mg/kg. This aggravation of adrenaline VTs may be explained simply by the additive increasing effect of OPC-18790 on the Ca current, which had already been increased by adrenaline and caused the arrhythmia.
OPC-18790 had no deleterious effect on the digitalis VT, and it is consistent with our previous proposal that the occurrence of digitalis VT is not influenced by the Ca channel activities (11, 13) . The practical importance of this result is that this new positive inotropic agent can be used in combination with digitalis without increasing the risk of arrhythmia, and this is a common observation among new positive inotropic drugs in our previous study (6) . In the present in vitro electrophysiological study of OPC-18790, it slightly shortened IVCT of the canine iso lated blood-perfused PM preparation, which is a unique effect but is probably not related to the drug effect on the Na channels. We reported that the lengthening effect of class I antiarrhythmic drugs on IVCT correlated well with the antiarrhythmic potency of these drugs on digitalis and coronary ligation VTs. In an in vivo study (1) , OPC 18790 decreased the AV conduction time, but had no effect on the intraventricular conduction. We do not know the reason for the discrepancy between the two results, but as judged by the high doses needed to produce these effects, they may not play a significant role in their effect on the arrhythmias.
The effect of OPC-18790 on coronary ligation-induced VTs was similar to vesnarinone, because it tended to ag gravate 48-hr coronary ligation VTs, but was different from that of vesnarinone in that OPC-18790 had no statistically significant effect on 24 and 48-hr coronary ligation VTs and did not induce ventricular fibrillation.
Vesnarinone (3 mg/kg) had no deleterious effect on 24-hr coronary ligation VT, but the same dose increased the arrhythmic ratio of 48-hr coronary ligation VT. These results indicate that OPC-18790 may be used for the treat ment of cardiac failure caused by myocardial damage. However, it should always be borne in mind that this drug is potentially arrhythmogenic, because of its Ca current and/or intracellular Ca concentration increasing effects that may generate or aggravate arrhythmia by inducing delayed afterdepolarizations (14, 15) . In conclusion, the new positive inotropic drug OPC 18790 was similar to the other new positive inotropic drugs we examined; i.e., it aggravated adrenaline induced VT, but did not change the digitalis and two-stage coro nary ligation VTs. This may indicate that there are elec trophysiological differences among these new positive iso tropic drugs: some have a negative inotropic effect; and some, like OPC-18790, have class III antiarrhythmic ac tion to prolong action potential duration or an additional positive inotropic mechanism, such as the Ca sensitizing effect of sulmazole, and do not have a strong influence on ventricular arrhythmias.
